{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:08:06Z","timestamp":1791122886011,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40265-025-02218-5","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:17:25Z","timestamp":1753885045000},"page":"1307-1310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Acoltremon: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2218_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106206","volume":"175","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, et al. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. 2022;175: 106206.","journal-title":"Eur J Pharm Sci"},{"key":"2218_CR2","unstructured":"Alcon Laboratories. Alcon announces FDA approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease [media release]. 28 May 2025. https:\/\/www.alcon.com."},{"key":"2218_CR3","unstructured":"Alcon Laboratories. TRYPTYR (acoltremon ophthalmic solution) 0.003% for topical ophthalmic use: US prescribing information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217370s000lbl.pdf. Accessed 22 Jul 2025."},{"key":"2218_CR4","unstructured":"Avizorex Pharma. AVIZOREX PHARMA, SL receives Notice of Allowance for U.S. Patent on AVX-012 compositions and methods of treatment for dry eye syndrome [media release]. 3 Mar 2015"},{"key":"2218_CR5","unstructured":"Alcon Laboratories. Alcon completes acquisition of Aerie Pharmaceuticals, Inc., strengthening companys ophthalmic pharmaceutical business [media release]. 22 Nov 2022. https:\/\/www.alcon.com."},{"key":"2218_CR6","unstructured":"Aerie Pharmaceuticals. Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma, S.L. to advance its dry eye program [media release]. 18 Nov 2019"},{"key":"2218_CR7","unstructured":"OcuMension Therapeutics.. OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship [media release]. 12 Aug 2024"},{"key":"2218_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.830853","volume":"9","author":"S Yang","year":"2022","unstructured":"Yang S, Wu Y, Wang C, et al. Ocular surface ion-channels are closely related to dry eye: key research focus on innovative drugs for dry eye. Front Med (Lausanne). 2022;9: 830853.","journal-title":"Front Med (Lausanne)."},{"key":"2218_CR9","unstructured":"Gupta PK, Paauw J, Shultz MC, et al. Total ocular staining reduction associated with acoltremon 0.003%, a novel TRPM8 agonist: results from ph3 pivotal studies. In: ASCRS Annual Meeting. 2025."},{"key":"2218_CR10","unstructured":"Periman LM, Kenyon KR, Boehmer B, et al. Treatment with acoltremon 0.003%, a novel TRPM8 agonist, improves multiple DED symptoms: results from phase 3 clinical studies. In: ASCRS Annual Meeting. 2025."},{"key":"2218_CR11","unstructured":"Periman LM, Pattar GR, McLaurin EB, et al. Symptom improvement with acoltremon 0.003% within 1 month of dosing: results from phase 3 pivotal clinical studies. In: ASCRS Annual Meeting. 2025."},{"key":"2218_CR12","unstructured":"Wirta DL, Garcia Santana SM, Almeida D, et al. Sustained tear production with acoltremon 0.003% over 12 months: results from Comet-4, a phase 3 long-term safety study. In: ASCRS Annual Meeting. 2025."},{"key":"2218_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","volume":"26","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Senchyna M, Lewis AE, et al. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022;26:166\u201373.","journal-title":"Ocul Surf"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02218-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02218-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:16:53Z","timestamp":1759241813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02218-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02218-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"16 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}